Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

U.S. drug distributors prevail in $2.5 billion West Virginia opioid case

Published 07/04/2022, 06:18 PM
Updated 07/04/2022, 11:15 PM
© Reuters. FILE PHOTO: Tablets of the opioid-based Hydrocodone at a pharmacy in Portsmouth, Ohio, June 21, 2017.  REUTERS/Bryan Woolston/File Photo
TEVA
-
CAH
-
WMT
-
MCK
-
COR
-
JNJ
-
CVS
-
WBA
-

By Nate Raymond

(Reuters) -Major U.S. drug distributors McKesson Corp (NYSE:MCK), AmerisourceBergen (NYSE:ABC) Corp and Cardinal Health Inc (NYSE:CAH) are not responsible for fueling an opioid epidemic in a part of West Virginia, a federal judge ruled on Monday.

U.S. District Judge David Faber rejected efforts by the city of Huntington and Cabell County to force the country's three largest pharmaceutical distributors to pay $2.5 billion to address a drug crisis prompted by a flood of addictive pills in their region.

But following a months-long trial that ended last year, Faber said the companies did not cause any oversupply of opioids, saying doctors' "good faith" prescribing decisions drove the volume of painkillers they shipped to pharmacies.

While the companies from 2006 to 2014 shipped 51.3 million opioid pills to retail pharmacies in the communities, "there is nothing unreasonable about distributing controlled substances to fulfill legally written prescriptions," Faber wrote.

"The opioid crisis has taken a considerable toll on the citizens of Cabell County and the city of Huntington," he wrote. "And while there is a natural tendency to assign blame in such cases, they must be decided not based on sympathy, but on the facts and the law."

Steve Williams, Huntington's mayor, in a statement called the decision "a blow to our city and community." The city had sought to force the companies to help fund opioid treatment programs.

The companies welcomed the ruling, which AmerisourceBergen said struck down the notion that the distribution of U.S. Food and Drug Administration-approved drugs to licensed health care providers could be deemed a public nuisance.

Cardinal Health and McKesson in separate statements said the distributors had maintained systems to prevent the diversion of opioids to illicit channels.

More than 3,300 lawsuits have been filed, largely by state and local governments, seeking to hold those and other companies responsible for an opioid abuse epidemic linked to more than 500,000 overdose deaths over the last two decades.

The distributors, along with drugmaker Johnson & (J&J (NYSE:JNJ)), last year agreed to pay up to $26 billion to resolve the thousands of lawsuits brought against them by state and local governments around the country.

But communities in hard-hit West Virginia opted against joining a national opioid settlement in favor of seeking a bigger recovery. Another trial pitting the distributors against West Virginia communities begins Tuesday in state court.

© Reuters. FILE PHOTO: Tablets of the opioid-based Hydrocodone at a pharmacy in Portsmouth, Ohio, June 21, 2017.  REUTERS/Bryan Woolston/File Photo

Monday's ruling adds to the mixed record for opioid cases that have gone to trial nationally, with courts in Oklahoma and California last year rejecting similar claims against drugmakers like J&J.

A federal jury in November found pharmacy chain operators CVS Health Corp (NYSE:CVS), Walgreens Boots Alliance (NASDAQ:WBA) Inc and Walmart (NYSE:WMT) Inc liable in a case filed by two Ohio counties. A New York jury found Teva Pharmaceutical Industries (NYSE:TEVA) Ltd liable in December in a case by the state and two counties.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.